Milestone Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Milestone Pharmaceuticals Inc. (MIST) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 66.39 thousand shares for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-13.
Discontinued › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2020-11-13
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-09-30 was 21.00K shares.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-06-30 was 37.66K shares.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-03-31 was 7.73K shares.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2019-12-31 was 81.10K shares.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 81.10K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2020-09-30 | 21.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | 58.66K shares derived: sum of 2 quarters · filed 2020-11-13 | 66.39K shares 10-Q · filed 2020-11-13 | 147.49K shares derived: sum of 4 quarters · filed 2020-11-13 |
| 2020-06-30 | 37.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | 45.39K shares 10-Q · filed 2020-08-12 | 126.48K shares derived: sum of 3 quarters · filed 2020-10-23 | 126.48K shares derived: sum of 4 quarters · filed 2020-11-13 |
| 2020-03-31 | 7.73K shares 10-Q · filed 2020-05-14 | 88.83K shares derived: sum of 2 quarters · filed 2020-10-23 | 88.83K shares derived: sum of 3 quarters · filed 2020-11-13 | 88.83K shares derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-12-31 | 81.10K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | 81.10K shares derived: sum of 2 quarters · filed 2020-11-13 | 81.10K shares derived: sum of 3 quarters · filed 2020-11-13 | 81.10K shares 10-K/A · filed 2020-10-23 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-13 | 0.00 shares 10-Q · filed 2020-11-13 | |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | 0.00 shares 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-06-19 | |||
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2019-11-13 | 12.20K shares 10-Q · filed 2019-11-13 | |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | 12.20K shares 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | 12.20K shares 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |